Economics of Health Care Systems

Smith, P.

Seminar Briefing
February 2020

Health System Strengthening (HSS) is an important concept now widely discussed, but too often without sufficient structure or an adequate understanding of what actually is involved. The articles on which this seminar is based (Morton, Thomas and Smith, 2016; Smith and Yip, 2016) attempted to present more clearly just what health system strengthening might entail and whether that might be modelled.

Towse, A., Hernandez-Villafuerte, K. and Shaw, B.
Consulting Report
May 2018

This OHE Consulting Report reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018) in which the authors argue for “greater transparency in drug pricing” and propose generating estimates of the cost of manufacturing essential medicines to inform negotiations on drug pricing.

OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.

OHE Lunchtime Seminar with Prof Peter Smith: ‘How can we evaluate the cost-effectiveness of health system strengthening? A platforms perspective’

OHE, in collaboration with RAND Europe and King’s College, has been awarded a research grant from Cancer Research UK exploring outcome-based payments.

OHE Consulting has produced a report summarising the literature on indication-based pricing and how it has been applied in the U.S. and 5 European countries.

On 13th of April 2018, EvaluAES held its 7th annual workshop on economic evaluation of health policies.

OHE is on RePEc: find publications from the Office of Health Economics in Research Papers in Economics.

OHE Consulting publishes a report on the barriers to the uptake of minimal access surgery in the NHS and private sector.

Ferraro, J., Towse, A., and Mestre-Ferrandiz, J.

Briefing
May 2017

Resistance to antibiotics is growing, posing a major health risk in rich and poor countries. Additional ways of rewarding R&D are required.

Mechanisms designed to encourage companies to undertake R&D on new medicines are generally characterised as either “push” or “pull” programs.

Pages

Subscribe to RSS - Economics of Health Care Systems